- Rodman & Renshaw cut Karyopharm Therapeutics to Neutral from Buy.
Rodman & Renshaw lowered its rating on Karyopharm Therapeutics to Neutral from Buy. The ratings summary carried no price target and no stated rationale. The change removes one buy call on the small-cap biotech without adding an outright sell rating.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.